drugset / Trial / NCT05751486

A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma

NCT05751486

Phase 1 Completed 64 enrolled Shanghai Junshi Bioscience Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS001sc monotherapy and combination with gemcitabine and cisplatin (GP) in patients with Advanced nasopharyngeal carcinoma.

Timeline

Start
2022-11-16
Primary completion
2023-12-30
Completion
2024-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Toripalimab Monoclonal antibody Subcutaneous